Amgen Reports 10% Revenue Growth to $10.054 Billion in Latest Quarter

Amgen Inc. reported significant financial growth in its latest quarterly results, with total revenues reaching $10.054 billion for the three months ended June 30, 2026, a 10% increase from $9.179 billion in the same period last year. Product sales were a major contributor, totaling $9.537 billion, up from $8.771 billion, driven by a 9% increase in U.S. sales and a 4% increase in sales from the rest of the world. The company's net income also saw a substantial rise, climbing 66% to $2.375 billion, or $4.37 per diluted share, compared to $1.432 billion, or $2.65 per diluted share, in the prior year.

The financial performance reflects a notable improvement in operating income, which increased by 32% to $3.514 billion, compared to $2.656 billion in the previous year. Operating expenses remained relatively stable at $6.540 billion, slightly up from $6.523 billion, with a decrease in cost of sales contributing to the overall profitability. The effective tax rate for the quarter was 14.2%, up from 8.7% in the prior year, primarily due to changes in the earnings mix and lower amortization expenses from acquisition-related assets.

Strategically, Amgen has made significant advancements, including the European Commission's approval of IMDELLTRA for treating extensive-stage small cell lung cancer. The company also continues to navigate challenges posed by macroeconomic conditions, including inflation and pricing pressures from government policies such as the Inflation Reduction Act and the 340B Drug Pricing Program. These factors have led to anticipated declines in net selling prices for some products, including ENBREL and Otezla, which are set for Medicare price setting in the coming years.

Operationally, Amgen's product portfolio showed varied performance, with notable increases in sales for Repatha, EVENITY, and TEZSPIRE, while Prolia and Otezla experienced declines. The company reported a 9% volume growth in the U.S. and a 10% growth in the rest of the world for the first half of 2026. As of June 30, 2026, Amgen's cash and cash equivalents stood at $13.989 billion, up from $9.129 billion at the end of 2025, reflecting strong cash flow from operations. The company remains committed to investing in innovation while returning capital to shareholders through dividends and potential stock repurchases, with $6.8 billion remaining under its stock repurchase authorization. Looking ahead, Amgen anticipates continued volume growth, albeit tempered by pricing pressures and evolving market conditions.